News

San Francisco-Large preoperative pupil size does not positively correlate with an increase in visual symptoms after wavefront-guided myopic LASIK, according to the results of a prospective study reported by researchers from Stanford University, Stanford, CA. The relationship between pupil size and quality of vision after LASIK is a source of controversy with various publications reporting different results, said Annie Chan, MD, who is in the residency program at the university's Department of Ophthalmology.

San Francisco-Results of the most recent American Society of Cataract and Refractive Surgery (ASCRS)/European Society of Cataract and Refractive Surgeons (ESCRS) survey on foldable IOLs requiring explantation or secondary intervention indicate a shift in the leading causes for these procedures, said Nick Mamalis, MD, professor of ophthalmology and visual sciences, University of Utah School of Medicine, Salt Lake City.

San Francisco-At the opening general session, Bradford J. Shingleton, MD, summarized the activities and accomplishments of the American Society of Cataract and Refractive Surgery (ASCRS) during his 1-year tenure as president of the organization.

San Francisco-The first session of a unique training program, Premium Lens Boot Camp, to help refractive and cataract surgeons grow their accommodating/multifocal lens business will be held June 5 at the O'Hare Marriott, Chicago.

San Francisco-Although the debate continues regarding the pros and cons of different approaches to antibiotic prophylaxis for postoperative endophthalmitis, available data are clear in demonstrating that it is critical to assure an effective concentration is present at the time of surgery and maintained in the early postoperative period, said Randall J. Olson, MD, John A. Moran Presidential Professor and chairman of the Department of Ophthalmology and Visual Sciences, University of Utah School of Medicine, Salt Lake City.

San Francisco-An interim analysis of data from an ongoing U.S. clinical trial shows corneal collagen crosslinking using riboflavin and ultraviolet A (UVA) light has promising efficacy and safety for the treatment of progressive keratoconus and postLASIK ectasia, said R. Doyle Stulting, MD, PhD, professor of ophthalmology, Emory University, Atlanta.

San Francisco-In eyes with normal endothelium requiring corneal transplantation, deep anterior lamellar keratoplasty (DALK) using Anwar's big-bubble technique can result in visual acuity outcomes that are at least as good as those experienced after penetrating keratoplasty (PKP) and with the advantage of causing fewer complications than the full thickness procedure, said Donald H. Tan, MD, deputy director and head, corneal service, Singapore National Eye Centre, and head and professor of ophthalmology, National University of Singapore.

The FDA has approved trypan blue ophthalmic solution 0.15% (MembraneBlue, Dutch Ophthalmic Research Center International, b.v.) for use as an aid during vitrectomy procedures by staining the epiretinal membranes and, thereby, facilitating the removal of tissue, according to a prepared statement.

Alimera Sciences Inc., has made available the interim, 12-month safety and efficacy data from the first human pharmacokinetic study of fluocinolone acetonide intravitreal insert (Iluvien), which is currently under development for the treatment of diabetic macular edema, the company said in a prepared statement.

HyperBranch Medical Technology Inc. has granted BD Medical-Ophthalmic Systems, a unit of Becton, Dickinson and Co., an exclusive worldwide license to market its liquid ocular bandage (OcuSeal), according to a prepared statement.

The FDA has accepted for review a supplemental new drug application submitted by Sirion Therapeutics Inc., which seeks market approval of difluprednate ophthalmic emulsion 0.05% (Durezol) for the treatment of endogenous anterior uveitis, according to a statement issued by Sirion.

iScience Interventional has launched a new surgeon support Web site, called iForum, that can be viewed at www.iforummd.com, according to a release issued by the company.

Bausch & Lomb and Pfizer have entered into a co-promotion agreement that involves both companies? prescription ophthalmic pharmaceuticals in the United States, the companies announced in a joint statement.